For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
Vistagen Therapeutics Inc (NASDAQ: VTGN) closed the day trading at $4.33 up 1.17% from the previous closing price of $4.28. In other words, the price has increased by $1.17 from its previous closing price. On the day, 1.0 million shares were traded. VTGN stock price reached its highest trading level at $4.42 during the session, while it also had its lowest trading level at $4.02.
Ratios:
For a better understanding of VTGN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.79 and its Current Ratio is at 5.79. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
On August 07, 2023, Maxim Group Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $30.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VTGN now has a Market Capitalization of 171015312 and an Enterprise Value of 95705304. For the stock, the TTM Price-to-Sale (P/S) ratio is 244.31 while its Price-to-Book (P/B) ratio in mrq is 2.54. Its current Enterprise Value per Revenue stands at 132.74 whereas that against EBITDA is -1.466.
Stock Price History:
The Beta on a monthly basis for VTGN is 0.22, which has changed by 0.6718147 over the last 52 weeks, in comparison to a change of 0.13506866 over the same period for the S&P500. Over the past 52 weeks, VTGN has reached a high of $5.14, while it has fallen to a 52-week low of $1.90. The 50-Day Moving Average of the stock is 6.03%, while the 200-Day Moving Average is calculated to be 44.71%.
Shares Statistics:
Over the past 3-months, VTGN traded about 645.36K shares per day on average, while over the past 10 days, VTGN traded about 1020500 shares per day. A total of 38.89M shares are outstanding, with a floating share count of 31.98M. Insiders hold about 19.03% of the company’s shares, while institutions hold 44.96% stake in the company. Shares short for VTGN as of 1763078400 were 1517368 with a Short Ratio of 2.35, compared to 1760486400 on 1338753. Therefore, it implies a Short% of Shares Outstanding of 1517368 and a Short% of Float of 5.4899998.
Earnings Estimates
. The current rating of Vistagen Therapeutics Inc (VTGN) reflects the combined expertise of 4.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.37, with high estimates of -$0.27 and low estimates of -$0.42.
Analysts are recommending an EPS of between -$1.43 and -$1.84 for the fiscal current year, implying an average EPS of -$1.71. EPS for the following year is -$1.64, with 4.0 analysts recommending between -$1.6 and -$1.73.
Revenue Estimates
A total of 5 analysts have provided revenue estimates for VTGN’s current fiscal year. The highest revenue estimate was $1.44M, while the lowest revenue estimate was $500k, resulting in an average revenue estimate of $891.8k. In the same quarter a year ago, actual revenue was $486k
